Harmony Biosciences (HRMY) Q3 2026 earnings review
Harmony Biosciences adds patients steadily, but patent royalties cut profit
Harmony Biosciences, the maker of the narcolepsy drug Wakix, added patients steadily while new patent payments cut into its profit. Revenue rose 12% to $269 million as the average number of patients grew by 400, keeping the business on pace for its unchanged full-year plan, which by our math leaves 13% growth for the fourth quarter. However, profit fell 5% because the drugmaker paid new royalties and a $25 million patent milestone to generic challengers it licensed patents from earlier this year, and chief executive Jeffrey Dayno announced he will retire at year-end.
| Wakix net revenue | $268.9M +12.3% from a year ago |
|---|---|
| Average patients on Wakix | 9,350 +400 from last quarter (+15.4% YoY) |
| Profit per share | $0.81 -7% from $0.87 a year ago |
| Full-year revenue outlook | Unchanged $1.00–1.04B (middle of the range: +17.5%) |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because steady commercial demand and encouraging 14-day safety data for its next-generation sleep drug BP-205 were offset by steeper royalty costs and executive turnover. The positive news is that a federal judge adopted the company's proposed schedule for a preliminary injunction decision by February 14, 2027 in its patent suit against AET Pharma and Sandoz. One caution: handing the chief executive role to chief operating officer Peter Anastasiou while the permanent finance chief seat remains open adds risk as the cash pile tops $1 billion.
The question now is whether the patent defense holds long enough and leaves enough profit margin for the pipeline to catch up. Either the court blocks generic entry in February and patient additions carry sales past $1 billion, or an adverse ruling and rising royalty tiers squeeze earnings ahead of rival drug launches in 2027. The court decisions due by February 14, 2027 and first-quarter efficacy data for BP-205 will decide.
🐂 Bull Case
Wakix Adds 400 Patients for a Fifth Quarter
Harmony Biosciences makes Wakix, the only non-scheduled prescription medicine for narcolepsy, a chronic sleep disorder. Steady patient additions are the engine behind its target of topping $1 billion in sales this year.
The company added 400 average patients this quarter to reach 9,350, up 15.4% from a year ago, after deploying an expanded sales and reimbursement team in the second quarter. Revenue rose 12.3% to $268.9 million. Growth slowed from 30.3% last quarter because last year's third quarter included an inventory build at wholesalers, so patient growth is the cleaner measure of demand.
What to watch: fourth-quarter net patient additions in February. Holding the pace near 400 additions would put full-year sales in the upper half of the company's $1.0 billion to $1.04 billion plan.
Early Data for BP-205 Arrives Ahead of Schedule
BP-205 is Harmony's experimental orexin-2 agonist, a new class of wakefulness drug designed to replace the brain chemical missing in narcolepsy patients. The drug group wants BP-205 to anchor its pipeline before Wakix loses patent protection, though the compound trails rival orexin drugs by several years and has not yet shown efficacy in humans.
The company released 14-day repeat-dosing safety data in 94 healthy volunteers a quarter earlier than planned and started a Phase 1b study in sleep-deprived volunteers. The drug stayed in the body with an average half-life of 29 hours, supporting once-daily dosing. "No liver or visual adverse events were reported, and no clinically significant cardiovascular events or EKG abnormalities were recorded," Harmony said, while insomnia and urinary urgency each occurred in under 20% of participants.
What to watch: Phase 1b efficacy data in sleep-deprived healthy volunteers in the first quarter of 2027. A clean wakefulness signal would support starting Phase 2 trials across multiple brain disorders by mid-2027.
🐻 Bear Case
New Patent Royalties Cut Into Profit Margins
To defend Wakix from generic copies, the neuroscience company licensed patents covering an amorphous form of pitolisant from generic makers Novitium and MSN Labs earlier this year. Management frames these agreements as a way to protect the franchise into the 2040s, but the deals carry an immediate cost on the income statement.
Profit fell even as sales grew 12.3%, cutting against the image of effortless earnings growth. Harmony said the drop came from "an increase in milestone charges and the new MSN royalty charges" alongside "new royalties related to the Novitium license agreement".
- Cost of making the product: 30.0% of revenue, up 5.1 percentage points from 24.9% a year ago
- Research and development: $71.7 million (26.6% of revenue), up 3.7 percentage points on a $25.0 million MSN patent milestone
- Operating income: $54.2 million, down 17.2% reported and down 1.6% by our math excluding R&D milestones in both periods
- Net income: $48.2 million ($0.81 per share), down 5.2% from $50.9 million
What to watch: cost of product sold as a share of revenue in the fourth quarter, when annual tiered royalties peak. A reading above 31% would show that the new patent licenses permanently lowered the profit margin on Wakix.
A February Court Ruling Decides Generic Entry
Wakix generates all of Harmony's revenue. Six of seven generic challengers settled to stay off the market until March 2030, assuming the drug wins pediatric exclusivity, which makes the courtroom fight with the seventh challenger, AET Pharma, the central legal test while a separate patent suit against AET and partner Sandoz adds a backup defense.
Closing arguments in the bench trial over Wakix's crystal-form and method-of-use patents finished on October 22. In the separate amorphous-patent lawsuit, the judge set a preliminary injunction hearing for January 26, 2027, with a decision due by February 14, 2027, when the regulatory freeze on generic approval expires. Harmony noted that "this schedule is identical to the preliminary injunction schedule Harmony proposed to the judge", but the substantive trial on that amorphous patent is not expected until 2029.
What to watch: the twin court rulings on the bench trial and the preliminary injunction around February 14, 2027. A loss on both would allow AET and Sandoz to launch a generic version three years before the 2030 settlement date.
Leadership Turnover Meets a $1 Billion Deal Budget
The Pennsylvania drugmaker has built a large cash reserve to buy new neuroscience medicines that can bring in sales between 2028 and 2032. While that cash pile gives the business self-funded firepower to diversify before 2030, executing major acquisitions during C-suite turnover raises the risk of a costly misstep.
Chief executive Jeffrey Dayno will retire on December 31, handing the role to chief operating officer Peter Anastasiou on January 1, 2027, just months after finance chief Glenn Reicin stepped down in July. "As I prepare to transition the President and CEO role to Peter on January 1, I believe Harmony is operating from a position of strength," Dayno said, and the company stated the change "does not change Harmony's previously communicated strategic priorities or the expected timing of key commercial and pipeline milestones". Yet cash and investments climbed 35.1% from a year ago to $1,051.6 million with no permanent finance chief named in the release.
What to watch: the appointment of a permanent chief financial officer and the terms of the first acquisition under Anastasiou. Signing a large deal before filling the finance seat would heighten execution risk.
Risks This Quarter Didn't Answer
Three standing risks around rival narcolepsy drugs, late-stage trial timelines, and patent litigation counterclaims remain open after the third-quarter release.
- Rival orexin drugs arriving around 2027: partner Bioprojet presented mouse data showing pitolisant works alongside an orexin agonist, supporting "concomitant use of an orexin-2 agonist and pitolisant as a potential therapeutic approach", but human prescribing trends after rival launches will test whether Wakix keeps its share.
- Late-stage trial timelines and pediatric exclusivity: topline data for both EPX-100 in rare epilepsies and the TEMPO study in Prader-Willi syndrome are now slated for mid-2027; completing TEMPO on time is required to lock in the six-month pediatric extension to March 2030.
- Antitrust counterclaims on patent settlements: the release gave no update on AET and Sandoz's antitrust challenges to the Novitium and MSN license deals, which the quarterly 10-Q filing will detail.
💲 Other KPIs
Money owed by customers and wholesalers grew much faster than sales. Trade receivables rose 26.9% from a year ago and 32.0% since December, while third-quarter revenue grew 12.3%. Receivables have climbed each quarter this year, from $96.8 million at year-end to $108.2 million, $111.0 million, and now $127.7 million, tying up more working capital.
Commercial spending rose while overhead shrank. Sales and marketing costs grew 17.5% from a year ago to $34.7 million after the drugmaker hired and deployed larger field sales, remote sales, and reimbursement teams in the second quarter. General and administrative costs fell 7.2% to $27.7 million because stock-based compensation declined.
Borrowings continued to shrink steadily. Total debt, combining the $20.0 million current portion and $129.1 million in long-term debt, fell 11.5% from $168.5 million a year ago and is down from $163.7 million at the end of 2025. Lower debt helped cut quarterly interest expense by 15.5% from a year ago to $3.1 million.
🔮 Guidance
Unchanged. The full-year plan still calls for about 17.5% revenue growth at the $1.02 billion middle of the range. By our math, that leaves $274.4 million for the fourth quarter, or 12.6% growth from a year ago, right in line with the third quarter's 12.3% pace. The floor of the range would require fourth-quarter growth to drop to 4.4%, making the upper half achievable if patient additions hold steady.
❓ Key Questions
When will Harmony name a permanent chief financial officer?
Chief executive Jeffrey Dayno retires on December 31 and finance chief Glenn Reicin left in July after three months. Investors need to know who will oversee financial discipline before the new chief executive spends the $1.05 billion cash pile on acquisitions.
What royalty rate will Wakix pay in the fourth quarter?
Cost of product sold jumped 5.1 percentage points to 30.0% of revenue on Novitium royalties, and the press release also cited new MSN royalty charges. Because Bioprojet royalties step up across the calendar year, fourth-quarter gross margin pressure could be even steeper.
Did wholesaler inventory shifts affect third-quarter revenue and receivables?
Average patients grew 15.4% from a year ago, revenue grew 12.3%, and net trade receivables climbed 32.0% since December to $127.7 million. Disclosing days of inventory on hand would show whether wholesalers built stock late in the quarter.
What happens to the 2030 settlements if TEMPO slips again?
The six generic settlement licenses allow entry no earlier than March 2030 if Wakix wins six months of pediatric exclusivity. That extension depends on completing the Phase 3 TEMPO trial in Prader-Willi syndrome, whose data readout previously moved from late 2026 to mid-2027.